Companies: 10,795·Total market cap: $144.5T
Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc.

AQSTNASDAQHealthcare● Active
$3.91
$-0.03(-0.64%)
Market Cap$387792414
P/E Ratio
52W High$7.55
52W Low$2.93
Overview

Aquestive Therapeutics, Inc. (AQST) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

aqst · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 10 Wall Street analysts in the past 3 months

SellBuy

Buy

10 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
0
Sell
0
Strong Sell
0
Total: 10 · Buy rate: 100.0%

12-Month Price Target

High

$12.00

Consensus

$9.00

+129.0% upside

Low

$6.00

Median: $9 · Last Close: $3.93

The Aquestive Therapeutics, Inc. (AQST) analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month AQST price target is $9.00, representing +129.0% upside from the current price of $3.93.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $9 (129.0%)

Consensus Target

$9.00

129.0% upside

High Target

$12

205.3%

Low Target

$6

52.7%

Current Price

$3.93

as of today

Based on analyst price targets, the AQST stock price prediction for the next 12 months ranges from $6 to $12. The consensus AQST price forecast of $9.00 implies 129.0% upside from the current price of $3.93.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$3.852.08%

1-day model range: $3.82–$3.88. Peak: $3.88 (-2.08%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$5+14.9%
2028$5+24.4%
2029$5+30.0%
2030$5+33.2%
2031+35.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)37.8Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · AQST · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$4.01SELL
MA 10$4.03SELL
MA 20$4.14SELL
MA 50$4.15SELL
MA 100$4.00SELL
MA 200$4.88SELL
Current $AQST · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.01SELL
EMA 10$4.04SELL
EMA 20$4.09SELL
EMA 50$4.14SELL
EMA 100$4.29SELL
EMA 200$4.39SELL
Current $AQST · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Piper Sandler2025-11-07
Maintains
OverweightOverweight
JMP Securities2025-10-09
Maintains
Market OutperformMarket Outperform
Oppenheimer2025-09-08
Maintains
OutperformOutperform
HC Wainwright & Co.2025-06-17
Maintains
BuyBuy
HC Wainwright & Co.2025-05-15
Maintains
BuyBuy
HC Wainwright & Co.2025-04-02
Maintains
BuyBuy
HC Wainwright & Co.2025-03-10
Maintains
BuyBuy
Lake Street2025-03-07
Maintains
BuyBuy
HC Wainwright & Co.2024-12-20
Maintains
BuyBuy
HC Wainwright & Co.2024-11-11
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Aquestive Therapeutics, Inc. (AQST) stock. Of the recent 54 rating actions, 1 were upgrades and 0 were downgrades. 10 analysts currently cover AQST.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

AQST analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$51M

↓ 49.8% YoY

Revenue Next Year

$70M

↑ 39.0% YoY

EPS This Year

$-0.42

EPS Next Year

$-0.44

↑ 5.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AQST EPS of $-0.42 for the current fiscal year, based on estimates from 4 analysts. The AQST revenue forecast is $51M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AQST stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AQST price target is $9.00 (+129.0% upside), with an analyst consensus of Buy.

The AQST short-term stock prediction for tomorrow is $3.85 (-2.08%). The AQST stock price prediction for 2027 estimates an average of $5. The AQST stock prediction for 2030 projects a range of $5–$6.

Aquestive Therapeutics, Inc. trades on NASDAQ under the ticker AQST. The AQST stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AQST forecast · 8 questions

According to 10 Wall Street analysts, the average 12-month AQST price target is $9.00, with a high forecast of $12.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +129.0% potential upside from the current price of $3.93.

AQST price targetWhat is AQST price targetAQST analyst price targetAQST 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.